HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 326 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Rapid, Robust and Durable Antitumour Activity of Pralsetinib in Patients with... August 26, 2022 Dormant Tumor Cells Can Be Sensitized to Chemotherapy February 20, 2019 FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC September 18, 2024 Doctors Think Woman Has A Brain Tumor, But Then They Open... June 17, 2019 Load more HOT NEWS French Senate Committee Backs ESMO Call to Revise EU Regulation to... Opinion: ‘Beating cancer means beating it for everyone’ Triplet Therapy with ADT, Docetaxel and Abiraterone Plus Prednisone Improves Survival... What to Know About Cancer Care and Research for People 65+:...
